Education
About Us
Working with TipRanks
Follow Us
Thomas Schall Insider Profile
11 Followers
Thomas Schall, President & CEO, Director at ChemoCentryx, holds 2.90K shares in Immuneering (Ticker: IMRX), holds 0.00 shares in ChemoCentryx (Ticker: CCXI). Most recently, Thomas Schall Bought ― shares of Immuneering on Mar 25, 2024 for an estimated value of 7.37K.
Thomas Schall ChemoCentryx (CCXI)President & CEO, Director
ChemoCentryx (CCXI)
President & CEO, Director
Not Ranked
Thomas Schall has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Director
Roles that Thomas Schall holds in companies
Most Profitable Insider Trade
The most profitable trade made by Thomas Schall
Thomas Schall's Trading History
ChemoCentryx
Oct 24, 2022
―
Uninformative Sell
―
$0.00
Immuneering
Mar 25, 2024
Director
Informative Buy
7.37K
$4.41K
List of latest transactions for each holding click on a transaction to see Thomas Schall's performance on stock
You May Also Like
Thomas Schall insider profile FAQ
What is the percentage of profitable transactions made by Thomas Schall?
The percentage of profitable transactions made by Thomas Schall is ―.
What is the average return per transaction made by Thomas Schall?
The average return per transaction made by Thomas Schall is ―.
What stocks does Thomas Schall hold?
Thomas Schall holds: CCXI, IMRX stocks.
What was Thomas Schall’s latest transaction?
Thomas Schall latest transaction was an Informative Buy of $7.37K.
What was Thomas Schall's most profitable transaction?
Thomas Schall’s most profitable transaction was an Informative Buy of IMRX stock on March 25, 2024. The return on the trade was -39.90%.
What is Thomas Schall's role in ChemoCentryx?
Thomas Schall's role in ChemoCentryx is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.